Wegene Biotech Completes Nearly RMB 100 Million Pre-B Financing to Build a Leading Domestic Platform for Monogenic Inherited Disease Testing

VCBeat has learned at the earliest opportunity,Shanghai Weihansi Biomedical Technology Co., Ltd. (hereinafter referred to as “Weihansi Biomedical”) announced the completion of its Pre-B financing round, raising nearly RMB 100 million, with exclusive investment from Huayao Capital. The funds raised in this round will be used to further advance the research and development of core product technologies, expand the product pipeline, and improve the layout of the industrial chain.

Previously, WeWeihansi Biomedical has received multiple rounds of investment from well-known industry institutions such as Matrix Partners China and Shengshan Assets.

We Health Biomedical, established in 2016, is a national high-tech enterprise anchored in genetic disease testing and strategically positioned in the reproductive health sector. ItsFocused on research in genetic testing technologies,Committed to developing advanced and innovative genetic testing technologies and diverse testing platforms,Focus on technological innovation and product portfolio development centered on blocking genetic variations.

Currently,we health BiomedicalWeihansi Biomedical has accumulated 31 patents, 33 software copyrights, 43 trademarks, and 28 registration certificates for Class II and Class III medical devices. Leveraging its robust technological innovation capabilities, Weihansi Biomedical has established a diversified genetic testing technology platform and actively engages in commercial and scientific collaborations across various testing scenarios, including birth defect prevention and control screening (three-tier prevention system), auxiliary diagnosis of genetic diseases, infertility and assisted reproductive testing, and kinship testing.

Gao Pengfei, Founder of We Health BiomedicalHe is among the earliest practitioners in China’s NGS market and in the specialized field of third-party clinical laboratory cellular and molecular genetics. With a background in biotechnology, he possesses extensive experience in sales and management. Hestated: “We Health BiomedicalStriving to build an integrated, advanced"An integrated development ecosystem combining a technological innovation platform for genetic diseases, an extensive biobank, standardized testing operations, and strong corporate qualifications, committed to becoming a leading enterprise in the field of genetic testing and a medical biotechnology company with enduring influence."

After four years of accumulation,WeiWe Health Biomedical’s business is growing rapidly at an average annual rate of 2–3 times.

The "Report on the Prevention and Control of Birth Defects in China (2012)," released in 2012, pointed out that there are approximately 900,000 new cases of birth defects annually in China, with an incidence rate of around 5.6%. Among these, about 250,000 cases involve clinically obvious birth defects visible at birth.

Clinical experts stated: “Eighty percent of birth defects are caused by genetic factors. In China, there are more than 8,000 types of genetic diseases with complex mutation patterns and a higher overall incidence rate. Meanwhile, genetic conditions may involve complex scenarios such as de novo mutations, which cannot be identified through routine testing. This not only increases the burden on society and families but also affects the subsequent reproductive choices of families affected by birth defects.”

Therefore，HeredityTesting is of great significance to reproductive health, not only can itIdentify the Etiology，To assist clinicians in better prognostic assessment and treatment,It can also be done throughGenetic CounselingEnsureReproductive Health，Prevention and control of birth defects. It is worth mentioning that, in genetic disease testing,Genetic Molecular Testing IsClinically Recognizedthe gold standard。

Gao Pengfei stated: “We Health Biomedical has secured multiple patents in the research and development of birth defect prevention and control screening (within the three-tier prevention system), bioinformatics analysis, report interpretation, and genetic counseling. The company has established a related genetic testing technology platform, providing comprehensive eugenics solutions for monogenic genetic diseases across the three stages of preconception, prenatal, and postpartum care. These solutions are at the leading level in China.

Meanwhile, We Health Biomedical has established strategic commercial partnerships for genetic disease testing with hundreds of top-tier medical institutions, enabling comprehensive detection of complex variant types, including structural variants, fusion gene variants, and mosaic variants.

Regarding the testing platform,We Health Biomedical has established various testing platforms, including first-generation sequencing, next-generation sequencing (Illumina, BGI), Bionano (structural variation detection platform), and qPCR. Gao Pengfei introduced: “Leveraging our existing comprehensive and advanced testing platform,We Health Biomedical is"Continuously refine various solutions for genetic disease testing and research, and persistently promote the widespread application of the latest genetic testing technologies in the field of medical science."

Based on this, We Health Biomedical centers on eugenics and expands outward into gene testing-related businesses. It has launched services including birth defect prevention and control screening, auxiliary diagnosis of genetic diseases, infertility and assisted reproductive technology diagnostics, kinship testing, and research services focused on genetic disorders. To date, We Health Biomedical has covered genetic auxiliary testing for monogenic diseases across more than 10 systemic genetic disease maps.

Furthermore, We Health Biomedical has achieved a major breakthrough in the field of non-invasive prenatal diagnosis for monogenic disorders (NIPD-MG), emerging as a leader in this domain. Following this round of financing, We Health Biomedical will further strengthen its advantages in adjunctive diagnosis of monogenic disorders and genetic testing of products of conception, thereby continuously fueling its rapid growth.

Founder of We Health BiomedicalGao Pengfeistated: “Thank you to both new and existing shareholders for theirwe health Biomedicalrecognition and support.we health BiomedicalThe value stems from the urgent demand for clinical genetic testing of hereditary diseases in China. We are committed to developing high-quality genetic testing products to help reduce the incidence of birth defects and the number of patients with hereditary disorders in China. Guided by our unwavering original aspiration and steadfast commitment, we will actively engage in complementary cooperation and synergistic development within the broader health sector with an open mindset, contributing more significantly to the overall improvement of national public health.”